Avedro, Inc. Company Profile

News Articles [9 Associated News Articles listed on BioPortfolio]

Avedro looks to launch $86M public offering

A prospectus has been filed by Avedro for an initial public offering in hopes of raising $86 million. -More- 

Ophthalmic device company Avedro plans $75M IPO

Ophthalmic medical systems company Avedro will offer 5 million shares at $14 to $16 each in hopes of raising $75 million in i -More- 

Avedro Starts U.S. IPO Effort

IPO Update: Avedro Files Proposed Terms For IPO

Avedro IPO: Speculative, But With An Ongoing Phase 3 Clinical Trial

Permanent J Code Issued for Avedro’s Photrexa® Drug Formulations

J Code 2787, Effective January 1, 2019, Expected to Streamline Reimbursement and Expand Patient Access Avedro, Inc., a leading commercial-stage ophthalmic med...

Anthem Blue Cross Blue Shield Joins List of 60 Commercial Plans Covering Avedro’s FDA-Approved Corneal Cross-Linking Procedure

Cross-linking now covered by the top five largest commercial insurance companies Avedro, Inc., a leading commercial-stage ophthalmic medical technology company a...

Cigna Is Newest Payer to Join Growing List of Commercial Plans Covering Avedro’s FDA-Approved Cross-Linking Procedure—133 Million Lives Covered in Total

Avedro Names Tim Homer Vice President of Health Policy & Market Access in Continued Effort to Expand Market Access and Reimbursement of Cross-Linking Avedro, ...

Drugs and Medications [1 Associated Drugs and Medications listed on BioPortfolio]

Photrexa viscous [avedro, inc.]

These highlights do not include all the information needed to use PHOTREXA VISCOUS and PHOTREXA safely and effectively. See full prescribing information for PHOTREXA VISCOUS and PHOTREXA. PHOTREXA VIS...

PubMed Articles [1 Associated PubMed Articles listed on BioPortfolio]

Corneal Cross-Linking: Current USA Status: Report From the Cornea Society.

The initial published clinical report on riboflavin/ultraviolet A corneal cross-linking (CXL) for treatment of progressive keratoconus dates back to 2003. CXL has since then been widely used outside t...

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Dietary Riboflavin (Vitamin B-2) and Cornea Cross-Linking

Corneal ectasia is characterized by irregularity and thinning of the cornea, causing the cornea to bulge forward and cause distorted vision and impaired visual acuity. Corneal ectasia is a...

Companies [2 Associated Companies listed on BioPortfolio]

Avedro, Inc.

Avedro, a privately held medical device company based in Waltham, MA, is developing the science of Thermo-biomechanics for therapeutic medical applications. Keraflex® KXL is th...

Avedro Inc.

Avedro is a privately held medical device and pharmaceutical company advancing the science and technology of corneal cross-linking and refractive correction. Avedro’s product...